Insider Selling: Invivyd, Inc. (NASDAQ:IVVD) Director Sells 74,764 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Terrance Mcguire sold 74,764 shares of the stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $0.47, for a total transaction of $35,139.08. Following the transaction, the director now owns 3,840,146 shares in the company, valued at approximately $1,804,868.62. The trade was a 1.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Stock Performance

NASDAQ IVVD traded down $0.01 during trading hours on Thursday, reaching $0.43. The stock had a trading volume of 1,644,881 shares, compared to its average volume of 657,806. Invivyd, Inc. has a 52-week low of $0.43 and a 52-week high of $5.20. The stock has a fifty day moving average of $0.80 and a 200 day moving average of $1.03. The stock has a market cap of $51.40 million, a P/E ratio of -0.22 and a beta of 0.53.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. EF Hutton Acquisition Co. I raised shares of Invivyd to a "strong-buy" rating in a research report on Wednesday, October 30th. Morgan Stanley reduced their price target on Invivyd from $9.50 to $3.55 and set an "overweight" rating on the stock in a research report on Wednesday, November 20th. D. Boral Capital reissued a "buy" rating and issued a $9.00 price objective on shares of Invivyd in a research report on Thursday, November 21st. Finally, HC Wainwright reduced their target price on Invivyd from $15.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, November 20th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $7.89.

Institutional Investors Weigh In On Invivyd

Several hedge funds have recently added to or reduced their stakes in IVVD. Proficio Capital Partners LLC acquired a new stake in Invivyd during the third quarter valued at $27,000. SG Americas Securities LLC grew its position in shares of Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company's stock valued at $42,000 after acquiring an additional 25,201 shares during the period. XTX Topco Ltd increased its stake in shares of Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company's stock valued at $42,000 after purchasing an additional 15,376 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new position in Invivyd in the 2nd quarter worth about $86,000. Finally, Rhumbline Advisers boosted its position in Invivyd by 4,434.1% during the second quarter. Rhumbline Advisers now owns 84,017 shares of the company's stock worth $92,000 after purchasing an additional 82,164 shares in the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.